The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Subjects

Trial Profile

The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs JNJ 42165279 (Primary)
  • Indications Anxiety disorders
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Oct 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
    • 25 Feb 2014 Planned End Date changed from 1 May 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 30 Sep 2013 Planned End Date changed from 1 Jan 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top